美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

AgomAb Therapeutics

15.90

-0.3100-1.91%

成交量：8.35万

成交额：132.26万

市值：7.75亿

市盈率：- -

高：17.45

开：16.54

低：15.08

收：16.21

52周最高：17.45

52周最低：12.66

股本：4,873.68万

流通股本：1,250.00万

量比：0.79

换手率：0.67%

股息：- -

股息率：- -

净资产收益率：--

总资产收益率：--

市净率：-4.36

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

Leerink Partners首次覆盖AgomAb Therapeutics，给予“跑赢大盘”评级，目标价36美元

旗舰企业 Generate Biomedicines 希望在美国 IPO 中获得 22 亿美元估值

异动解读 | 新股上市遇冷，AgomAb Therapeutics盘中大跌18.72%

比利时 Agomab Therapeutics 纳斯达克首秀股价下跌，估值 7.16 亿美元

比利时抗纤维化生物技术公司AgomAb Therapeutics(AGMB.US)启动美股IPO 拟募资2亿美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/AGMB/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AGMB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","market":"US","secType":"STK","nameCN":"AgomAb Therapeutics","latestPrice":15.9,"timestamp":1772571600000,"preClose":16.21,"halted":0,"volume":83498,"delay":0,"changeRate":-0.019123997532387443,"floatShares":12500000,"shares":48736779,"eps":0,"marketStatus":"盘前交易","change":-0.31,"latestTime":"03-04 07:54:02 EST","open":16.54,"high":17.4528,"low":15.08,"amount":1322601.8275,"amplitude":0.146379,"askPrice":17.91,"askSize":100,"bidPrice":13.61,"bidSize":100,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772634600000},"marketStatusCode":1,"adr":0,"listingDate":1770354000000,"exchange":"NASDAQ","adjPreClose":15.9,"postHourTrading":{"tag":"盘后","latestPrice":15.9,"preClose":15.9,"latestTime":"16:10 EST","volume":3,"amount":47.7,"timestamp":1772572204506,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7913127711951259},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AGMB\",,,,,undefined,":{"symbol":"AGMB","floatShares":12500000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7913127711951259,"shares":48736779,"dividePrice":0,"high":17.4528,"amplitude":0.146379,"preClose":16.21,"low":15.08,"week52Low":12.66,"pbRate":"-4.36","week52High":17.4528,"institutionHeld":0,"latestPrice":15.9,"eps":0,"divideRate":0,"volume":83498,"delay":0,"ttmEps":0,"open":16.54,"prevYearClose":16,"prevWeekClose":16.02,"prevMonthClose":16.02,"prevQuarterClose":16,"fiveDayClose":15.99,"twentyDayClose":16,"sixtyDayClose":16},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AGMB\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AGMB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AGMB\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/AGMB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"AGMB","date":"2026-03-03","current":-14.725744,"percent":0,"low":-14.725744,"twenty":-14.297058,"median":-13.901135,"eighty":-13.682416,"high":-12.965993,"avg":-13.942329,"sd":0.447673,"marketCap":790023187},"quantilePoints":[{"date":"2026-02-06","current":-14.293959,"twenty":-14.293959,"median":-14.293959,"eighty":-14.293959,"marketCap":779788464},{"date":"2026-02-13","current":-13.901135,"twenty":-14.202947,"median":-13.85921,"eighty":-13.805127,"marketCap":763217959},{"date":"2026-02-20","current":-13.975141,"twenty":-14.020702,"median":-13.811207,"eighty":-13.436782,"marketCap":760781120},{"date":"2026-02-27","current":-14.297833,"twenty":-14.274685,"median":-13.837477,"eighty":-13.631029,"marketCap":780275831},{"date":"2026-03-03","current":-14.725744,"twenty":-14.297058,"median":-13.901135,"eighty":-13.682416,"marketCap":790023187}],"updateTime":1772628842121},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AGMB\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1119430627","title":"Leerink Partners首次覆盖AgomAb Therapeutics，给予“跑赢大盘”评级，目标价36美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1119430627","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119430627?lang=zh_cn&edition=fundamental","pubTime":"2026-03-03 19:56","pubTimestamp":1772538974,"startTime":"0","endTime":"0","summary":"投资银行Leerink Partners宣布启动对生物技术公司AgomAb Therapeutics（AGMB）的研究覆盖，并给予“跑赢大盘”评级。该机构为该公司设定了36美元的目标股价，显示出对其未来增长潜力的积极预期。\n此次覆盖标志着市场对AgomAb Therapeutics研发管线的关注升温。Leerink Partners的看好评级基于对公司核心技术与业务前景的深入评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AGMB"],"gpt_icon":0},{"id":"2613789435","title":"旗舰企业 Generate Biomedicines 希望在美国 IPO 中获得 22 亿美元估值","url":"https://stock-news.laohu8.com/highlight/detail?id=2613789435","media":"路透中文","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613789435?lang=zh_cn&edition=fundamental","pubTime":"2026-02-23 19:54","pubTimestamp":1771847674,"startTime":"0","endTime":"0","summary":"更新版 3-旗舰企业 Generate Biomedicines 希望在美国 IPO 中获得 22 亿美元估值在第 3、6、7 段添加分析师评论Arasu Kannagi Basil路透2月23日 - 药物开发商Generate Biomedicines周一表示，该公司在美国首次公开募股的目标估值将高达21.7亿美元，从而进入上市步伐加快的生物技术市场。Aktis Oncology AKTS.O、Agomab Therapeutics AGMB.O、Veradermics MANE.N、Eikon Therapeutics EIKN.O和SpyGlass Pharma SGP.O今年已经登陆美国资本市场。\"Generate公司用于治疗严重哮喘的主要候选产品GB-0895正在进行后期试验。预计这项研究将于 2028 年上半年全部完成。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nL4S3ZJ0Q2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836757.USD","LU2028103732.USD","AMGN","BK4139","LU2750360997.AUD","LU0234570918.USD","LU2471134796.USD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD","LU0320765992.SGD","LU0096364046.USD","BK4550","LU1162221912.USD","BK4566","LU1868836914.USD","MRNA","SGP","BK4532","LU0889565916.HKD","LU2265009873.SGD","BK4552","IE0009355771.USD","LU1244550494.USD","LU0122379950.USD","LU0795875169.SGD","LU2133065610.SGD","EIKN","LU0251142724.SGD","LU1791807156.HKD","IE0004091025.USD","BK4127","LU2089283258.USD","LU0098860793.USD","LU0912757837.SGD","LU2111349929.HKD","LU2237443465.HKD","MRNY","MRNX","BK4534","MANE","LU2750360641.GBP","LU0106261372.USD","PIPR","BK4516","IE00BKVL7J92.USD","AGMB","AKTS","LU1804176565.USD","LU2237443622.USD","GSX"],"gpt_icon":0},{"id":"1129897501","title":"异动解读 | 新股上市遇冷，AgomAb Therapeutics盘中大跌18.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=1129897501","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129897501?lang=zh_cn&edition=fundamental","pubTime":"2026-02-07 01:54","pubTimestamp":1770400445,"startTime":"0","endTime":"0","summary":"AgomAb Therapeutics(AGMB)今日盘中股价大跌18.72%，引起了市场的广泛关注。消息面上，该公司于周五正式登陆美股市场，但新股表现不佳，开盘即大幅下跌。根据相关报道，其IPO价格为16美元，上市后股价持续走低，市场对其首秀反应冷淡。AgomAb Therapeutics是一家总部位于比利时的临床阶段生物制药公司，专注于开发针对免疫与炎症疾病的创新疗法。公司估值约为7.164亿美元，其核心候选药物针对纤维狭窄型克罗恩病等慢性纤维化适应症。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["AGMB"],"gpt_icon":0},{"id":"2609513671","title":"比利时 Agomab Therapeutics 纳斯达克首秀股价下跌，估值 7.16 亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2609513671","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609513671?lang=zh_cn&edition=fundamental","pubTime":"2026-02-07 01:42","pubTimestamp":1770399754,"startTime":"0","endTime":"0","summary":"比利时 Agomab Therapeutics 纳斯达克首秀股价下跌，估值 7.16 亿美元路透2月6日 - Agomab Therapeutics AGMB.O周五在纳斯达克首次上市时股价下跌约8%，这家总部位于比利时的公司估值为7.164亿美元。(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nL4T3Z21UV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGMB"],"gpt_icon":0},{"id":"2607091502","title":"比利时抗纤维化生物技术公司AgomAb Therapeutics(AGMB.US)启动美股IPO 拟募资2亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607091502","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607091502?lang=zh_cn&edition=fundamental","pubTime":"2026-01-30 15:16","pubTimestamp":1769757418,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，比利时二期生物科技公司AgomAb Therapeutics于美东时间周四公布了其美股IPO条款。该公司专注于开发针对克罗恩病及其他纤维化疾病的TGFβ抑制剂。按拟议发行价区间中值计算，AgomAb Therapeutics的完全稀释后市值将达到8.75亿美元。AgomAb Therapeutics是一家临床阶段生物制药公司，致力于开发针对免疫与炎症疾病的创新疾病修正疗法。AgomAb Therapeutics成立于2017年，计划以股票代码“AGMB”在纳斯达克上市。公司预计将于今年2月完成IPO定价。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4539","AGMB","BK4588","VT","BK4139","BK4585","BK4007","LENZ"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":5,"code":"91000000","status":"200"}]}}